(Updated - February 14, 2018 4:20 PM EST)

Prothena Corp. (NASDAQ: PRTA) reported Q4 EPS of ($1.24), $0.24 better than the analyst estimate of ($1.48). Revenue for the quarter came in at $229 thousand versus the consensus estimate of $240 thousand.

• Prothena reported a net loss of $47.8 million and $153.2 million for the fourth quarter and full year of 2017, respectively, as compared to a net loss of $48.9 million and $160.1 million for the fourth quarter and full year of 2016, respectively. Net loss per share for the fourth quarter and full year of 2017 was $1.24 and $4.07, respectively, as compared to a net loss per share of $1.41 and $4.66 for the fourth quarter and full year of 2016, respectively.
• Prothena reported total revenue of $0.2 million and $27.5 million for the fourth quarter and full year of 2017, respectively, as compared to total revenue of $0.2 million and $1.1 million for the fourth quarter and full year of 2016, respectively. The increase in revenue for the full year of 2017 was primarily due to achievement of a clinical milestone payment from Roche of $30.0 million, of which $26.6 million was recognized as collaboration revenue and $3.4 million was recognized as an offset to research and development expenses.

For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.

Earnings Guidance